What's in Queensland Centre for Gynaecological Cancer's pipeline?

Queensland Centre for Gynaecological Cancer has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Queensland Centre for Gynaecological Cancer's portfolio?

Top competitors by shared drug class: AstraZeneca, Chinese Academy of Medical Sciences, Intergroupe Francophone de Cancerologie Thoracique, Jiangsu Cancer Institute & Hospital, Jiangsu HengRui Medicine Co., Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/queensland-centre-for-gynaecological-cancer.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Queensland Centre for Gynaecological Cancer — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Queensland Centre for Gynaecological Cancer pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Paclitaxel, Carboplatin	Paclitaxel, Carboplatin	marketed	Chemotherapy combination (taxane + platinum agent)	Microtubules (paclitaxel); DNA (carboplatin)	Oncology

Therapeutic area mix

Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AstraZeneca · 1 shared drug class
Chinese Academy of Medical Sciences · 1 shared drug class
Intergroupe Francophone de Cancerologie Thoracique · 1 shared drug class
Jiangsu Cancer Institute & Hospital · 1 shared drug class
Jiangsu HengRui Medicine Co., Ltd. · 1 shared drug class
Samsung Medical Center · 1 shared drug class
Sanofi · 1 shared drug class
Spanish Lung Cancer Group · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Queensland Centre for Gynaecological Cancer:

Cite this brief

Drug Landscape (2026). Queensland Centre for Gynaecological Cancer — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/queensland-centre-for-gynaecological-cancer. Accessed 2026-05-17.